National Scleroderma Foundation is located in Danvers, MA. The organization was established in 1985. According to its NTEE Classification (H40) the organization is classified as: Diseases of Specific Organs Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. National Scleroderma Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 06/2022, National Scleroderma Foundation generated $4.6m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 0.8% each year. All expenses for the organization totaled $6.2m during the year ending 06/2022. While expenses have increased by 3.3% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, National Scleroderma Foundation has awarded 75 individual grants totaling $13,257,909. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE NATIONAL SCLERODERMA FOUNDATION'S MISSION IS TO ADVANCE MEDICAL RESEARCH, PROMOTE DISEASE AWARENESS, AND PROVIDE SUPPORT AND EDUCATION TO PEOPLE WITH SCLERODERMA, THEIR FAMILIES AND SUPPORT NETWORKS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
A RELENTLESS FORCE IN FINDING A CURE AND IMPROVING THE LIVES OF PEOPLE AFFECTED BY SCLERODERMA, THE NATIONAL SCLERODERMA FOUNDATION ADVANCES MEDICAL RESEARCH, PROMOTES DISEASE AWARENESS, AND PROVIDES SUPPORT AND EDUCATION TO PEOPLE WITH SCLERODERMA, THEIR FAMILIES AND SUPPORT NETWORKS. SUPPORTED BY A NETWORK OF THOUSANDS OF INDIVIDUALS ACROSS THE UNITED STATES, THE FOUNDATION IS THE LEADING NONPROFIT FUNDER OF PEER-REVIEWED RESEARCH TO DISCOVER THE CAUSE, UNDERSTAND THE MECHANISMS, AND OVERCOME SCLERODERMA FOREVER. SUPPORT: THE FOUNDATION SERVES PEOPLE LIVING WITH SCLERODERMA, AS WELL AS THEIR CAREGIVERS AND FAMILY MEMBERS BY PROVIDING ACCESS TO SUPPORT GROUPS. IN THE WAKE OF THE PANDEMIC, THE FOUNDATION PIVOTED FROM IN-PERSON TO VIRTUAL COMMUNITY SUPPORT, ALLOWINGN FOR MEMBERS OF THE SCLERODERMA COMMUNITY TO CONNECT NO MATTER WHERE THEY WERE IN THE COUNTRY. THIS ALSO ALLOWED FOR THE CREATION OF MORE TARGETED, TOPICAL SUPPORT GROUPS SUCH AS ONE FOR MEN, WHICH MAKE UP JUST 20% OF THE POPULATION IMPACTED BY SCLERODERMA, AND BIPOC, AS WELL AS YOUNG ADULTS. EDUCATION: THE FOUNDATION PROVIDES EDUCATION ABOUT HOW TO LIVE BETTER WITH SCLERODERMA FOR THOSE AFFECTED BY THE DISEASE, AS WELL AS THEIR CAREGIVERS, FAMILIES AND SUPPORT NETWORKS. THE FOUNDATION IS ALSO A CME AND CNE PROVIDER, EDUCATING HEALTHCARE PROVIDERS ABOUT SIGNS AND SYMPTOMS, TIMELY DIAGNOSIS, AND CUTTING-EDGE TREATMENTS AND THERAPIES. THE NATIONAL SCLERODERMA CONFERENCEATTRACTS MORE THAN 500 PARTICIPANTS ANNUALLY. IN THE WAKE OF THE PANDEMIC, THE FOUNDATION PIVOTED FROM IN-PERSON TO VIRTUAL COMMUNITY SUPPORT, PROVIDING WORLD CLASS EDUCATION AND NETWORKING OPPORTUNITIES FOR THE COMMUNITY VIA A NATIONAL WEBINAR SERIES THAT WAS, FOR THE FIRST TIME, OFFERED VIRTUALLY. THE WEBINARS OFFERED EDUCATION AND NETWORKING OPPORTUNITIES FOR PEOPLE LIVING WITH SCLERODERMA, CAREGIVERS, FAMILY MEMBERS AND FRIENDS. IT ALSO WAS AN EXCELLENT RESOURCE FOR PHYSICIANS AND OTHER HEALTHCARE PROFESSIONALS, WHO ALSO NEED COMPREHENSIVE INFORMATION ABOUT THE DISEASE.
RESEARCH:IN 2021, THE FOUNDATION MADE A COMMITMENT TO MORE THAN DOUBLE ITS RESEARCH FUNDING, (ITS SINGLE LARGEST EXPENSE) COMITTING $2.4 MILLION IN FY 2022. THIS FUNDING AIMS TO STIMULATE AND SUPPORT RESEARCH TO BETTER UNDERSTAND THE MECHANISMS THAT CAUSE THE DISEASE, HOW TO PREVENT AND ACCURATELY DIAGNOSIS AND TREAT THE DISEASE, AND ULTIMATELY FIND A CURE FOR SCLERODERMA. EACH AWARD IS $200,000 SPREAD OVER MULTIPLE YEARS. IN FY 2022, FIVE AWARDS WERE TWO-YEAR ESTABLISHED INVESTIGATOR AWARDS, AND SEVEN AWARDS WERE THREE-YEAR NEW INVESTIGATOR AWARDS. NEW INVESTIGATOR AWARDS ARE INTENDED TO HELP EMERGING SCIENTISTS GATHER SUFFICIENT DATA TO DEMONSTRATE THE VALUE OF THEIR AREA OF INVESTIGATION AND ATTRACT LARGER FUNDING FROM OTHER SOURCES. THE FOUNDATION'S PEER REVIEWED RESEARCH GRANTS PROGRAM PRIORITIZES SCIENTIFIC MERIT AND IS ADMINISTERED BY THE FOUNDATION'S RESEARCH COMMITTEE. THIS COMMITTEE, COMPOSED OF SCLERODERMA EXPERTS FROM ACROSS THE COUNTRY, MAKES FUNDING RECOMMENDATIONS TO THE BOARD OF DIRECTORS ANNUALLY AFTER A RIGOROUS PEER REVIEW PROCESS.EACH GRANT APPLICATION CONTAINS VERY SPECIFIC ELIGIBILITY AND REVIEW CRITERIA. DETAILS REGARDING THESE REQUIREMENTS ARE AVAILABLE AT WWW.SCLERODERMA.ORG. ALL APPLICATIONS UNDERGO RIGOROUS PEER REVIEW BY HIGHLY RESPECTED SCIENTIFIC EXPERTS IN THE FIELD. ONLY PROJECTS OF SIGNIFICANT SCIENTIFIC MERIT ARE RECOMMENDED FOR FUNDING. PEER REVIEW RANKINGS ARE SENT TO THE FOUNDATION'S RESEARCH COMMITTEE FOR QUALIFICATION BEFORE BEING PRESENTED TO THE FOUNDATION BOARD OF DIRECTORS FOR FINAL APPROVAL AND FUNDING. AFTER THE AWARDS ARE MADE, ALL RECIPIENTS ARE REQUIRED TO COMPLETE FUNDING CONTRACTS WITH INSTITUTIONAL SIGN-OFF AND MUST ALSO SUBMIT ANNUAL REPORTS ON THEIR PROGRESS. ALL REPORTS ARE REVIEWED BY THE FOUNDATION'S RESEARCH COMMITTEE TO ENSURE COMPLIANCE WITH PROGRAMMATIC, SCIENTIFIC, AND FISCAL AND ADMINISTRATIVE POLICES AND REQUIREMENTS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Michael B Hyde Coo/cfo | Officer | 40 | $129,165 |
Mary J Wheatley CEO (since July 1, 2021) | Officer | 40 | $101,145 |
Robert J Riggs CEO (until Dec 2021) | Officer | 40 | $83,028 |
Cos Mallozzi Chair | OfficerTrustee | 2 | $0 |
Mike Levengood Secretary | OfficerTrustee | 2 | $0 |
Carol Feghali-Bostwick PHD Vice Chair | OfficerTrustee | 2 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Blackbaud Inc Website Support | 6/29/22 | $205,065 |
Robert Halfaccountemps Temporary Staffing Services | 6/29/22 | $132,631 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $443,271 |
Related organizations | $0 |
Government grants | $249,960 |
All other contributions, gifts, grants, and similar amounts not included above | $3,769,199 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $4,462,430 |
Total Program Service Revenue | $0 |
Investment income | $175,431 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | -$56,394 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $4,581,467 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $2,425,000 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $419,642 |
Compensation of current officers, directors, key employees. | $249,564 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $1,348,328 |
Pension plan accruals and contributions | $17,145 |
Other employee benefits | $89,123 |
Payroll taxes | $137,959 |
Fees for services: Management | $0 |
Fees for services: Legal | $60,000 |
Fees for services: Accounting | $47,550 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $25,203 |
Fees for services: Other | $456,014 |
Advertising and promotion | $21,037 |
Office expenses | $172,177 |
Information technology | $371,766 |
Royalties | $0 |
Occupancy | $192,742 |
Travel | $65,808 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $113,863 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $15,701 |
Insurance | $77,111 |
All other expenses | $0 |
Total functional expenses | $6,210,712 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $2,683,332 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $635,411 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $185,646 |
Net Land, buildings, and equipment | $29,987 |
Investments—publicly traded securities | $7,887,043 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $41,655 |
Total assets | $11,463,074 |
Accounts payable and accrued expenses | $208,675 |
Grants payable | $2,620,835 |
Deferred revenue | $4,529 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $79,414 |
Total liabilities | $2,913,453 |
Net assets without donor restrictions | $6,893,709 |
Net assets with donor restrictions | $1,655,912 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $11,463,074 |
Over the last fiscal year, National Scleroderma Foundation has awarded $2,425,000 in support to 13 organizations.
Grant Recipient | Amount |
---|---|
Pittsburgh, PA PURPOSE: RESEARCH | $200,000 |
Baltimore, MD PURPOSE: RESEARCH | $200,000 |
Boston, MA PURPOSE: RESEARCH | $200,000 |
UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER PURPOSE: RESEARCH | $200,000 |
Pittsburgh, PA PURPOSE: RESEARCH | $200,000 |
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY PURPOSE: RESEARCH | $200,000 |
Over the last fiscal year, we have identified 1 grants that National Scleroderma Foundation has recieved totaling $325.
Awarding Organization | Amount |
---|---|
The Butzel Long Charitable Trust Detroit, MI PURPOSE: THE NATIONAL SCLERODERMA FOUNDATION IS A 501 (C) (3) ORGANIZATION TO ADVANCE MEDICAL RESEARCH, PROMOTE DISEASE AWARENESS, AND PROVIDE SUPPORT AND EDUCATION TO PEOPLE WITH SCLERODERMA | $325 |
Beg. Balance | $1,881,204 |
Earnings | -$155,307 |
Other Expense | $69,985 |
Ending Balance | $1,655,912 |
Organization Name | Assets | Revenue |
---|---|---|
National Scleroderma Foundation Danvers, MA | $11,463,074 | $4,581,467 |
Usher 1f Collaborative Inc Newtonville, MA | $1,300,335 | $1,082,978 |
Termeer Foundation Inc Marblehead, MA | $1,750,365 | $259,546 |
Scleroderma Foundation Tri State Chapter Inc Binghamton, NY | $974,224 | $314,907 |
Foundation For Reproductive Medicine New York, NY | $63,851 | $0 |
Cgat Research Foundation Inc Needham, MA | $20,131 | $0 |
Salgi Esophageal Cancer Research Foundation East Greenwich, RI | $342,323 | $90,543 |
Overcoming Multiple Sclerosis Usa Inc Brooklyn, NY | $37,871 | $0 |
International Childrens Continence Society Inc Chappaqua, NY | $195,461 | $0 |
Domar Foundation Inc Waltham, MA | $38,156 | $0 |
New York Fertility Research Foundation Inc New York, NY | $67,492 | $0 |
New Age Research Foundation New Hyde Park, NY | $8,129 | $0 |